基于口腔和肠道细菌菌群探索治疗尿路上皮癌患者的预测因素。

Exploration of predictive factors based on oral and intestinal bacterial flora for treating patients with urothelial carcinoma.

作者信息

Matsumoto Yuichi, Hitaka Yukihiro, Hirata Hiroshi, Yamamoto Yoshiaki, Kobayashi Keita, Isoyama Naohito, Matsubara Toshio, Watanabe Kenji, Mizukami Yoichi, Nakagawa Shin, Mishima Katsuaki, Harada Koji, Shiraishi Koji

机构信息

Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.

Department of Urology, Sanyo-Onoda Municipal Hospital, Sanyo-Onoda, Yamaguchi, Japan.

出版信息

PLoS One. 2025 Jun 18;20(6):e0324814. doi: 10.1371/journal.pone.0324814. eCollection 2025.

Abstract

PURPOSE

The role of intestinal flora in carcinogenesis and chemotherapy efficacy has been increasingly studied; however, comparisons between oral and intestinal flora remain limited. Given the oral microbiome's role in systemic inflammation and immune modulation, it may significantly influence cancer progression and response to immunotherapy. This study aimed to identify the microbial changes in urothelial carcinoma (UC) by analyzing oral saliva and stool samples from healthy individuals and UC patients. We also examined the association between microbial composition and immune checkpoint inhibitor (ICI) response.

METHODS

A total of 20 healthy individuals and 38 patients with UC were analyzed. Among them, 27 patients with UC underwent ICI treatment. Oral saliva and stool samples were analyzed for 16S rRNA sequences to assess bacterial composition. Operational taxonomic units were generated, and phylogenetic analysis was performed using the Illumina BaseSpace.

RESULTS

Patients with UC showed higher Veillonellaceae and Prevotellaceae levels in saliva and stool, with lower levels of these bacteria associated with more prolonged overall survival and progression-free survival, particularly Veillonellaceae in stool. A higher neutrophil-to-lymphocyte ratio correlated with increased levels of these bacteria.

CONCLUSION

Veillonellaceae and Prevotellaceae are potential microbial biomarkers of survival outcomes and ICI efficacy in patients with UC. Non-invasive oral microbial sampling may facilitate personalized cancer treatment strategies.

摘要

目的

肠道菌群在致癌作用和化疗疗效中的作用已得到越来越多的研究;然而,口腔菌群和肠道菌群之间的比较仍然有限。鉴于口腔微生物群在全身炎症和免疫调节中的作用,它可能会显著影响癌症进展和对免疫治疗的反应。本研究旨在通过分析健康个体和尿路上皮癌(UC)患者的口腔唾液和粪便样本,确定UC中的微生物变化。我们还研究了微生物组成与免疫检查点抑制剂(ICI)反应之间的关联。

方法

共分析了20名健康个体和38名UC患者。其中,27名UC患者接受了ICI治疗。对口腔唾液和粪便样本进行16S rRNA序列分析,以评估细菌组成。生成操作分类单元,并使用Illumina BaseSpace进行系统发育分析。

结果

UC患者唾液和粪便中的韦荣氏菌科和普雷沃氏菌科水平较高,这些细菌水平较低与更长的总生存期和无进展生存期相关,尤其是粪便中的韦荣氏菌科。较高的中性粒细胞与淋巴细胞比率与这些细菌水平的增加相关。

结论

韦荣氏菌科和普雷沃氏菌科是UC患者生存结果和ICI疗效的潜在微生物生物标志物。非侵入性口腔微生物采样可能有助于制定个性化的癌症治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/994b/12176287/f5f72b1428a8/pone.0324814.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索